RxDoctor Payments Data

Rafia Shafqat, MD

Neurology · Circleville, OHNPI 1558737346

Payments from drug & device makers

$12,750in general payments, 2019–2025

Across 85 payments — averaging $150.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$9K
  • Lilly USA, LLC$801
  • AbbVie$779
  • Eisai Inc.$298
  • Axsome Therapeutics, Inc.$199
  • Teva Pharmaceuticals USA, Inc.$190
  • plus $1K from 13 others

What the payments were for

  • Consulting fees$1,52512%
  • Speaking & faculty fees$7,52059%
  • Food & beverage$3,49227%
  • Education$2142%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,750 in reported general payments places this provider in the 65th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$92,385
Medicare patients
233
Services billed
6,362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate71$78,568
QuliptaAtogepant61$73,708
Aimovig AutoinjectorErenumab-Aooe55$40,683
UbrelvyUbrogepant24$31,884
Emgality PenGalcanezumab-Gnlm29$20,526
VimpatLacosamide12$12,229
XcopriCenobamate41$10,607
NeuproRotigotine12$9,956
Carbidopa-LevodopaCarbidopa/Levodopa76$2,625
Gabapentin119$1,552
Lacosamide41$1,504
Pregabalin31$1,396
Levetiracetam62$1,333
Sumatriptan Succinate73$1,119
Memantine Hcl72$1,035

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$779$105,59285 claims
PfizerNurtec Odt$9,251$78,56871 claims
UCB, Inc.Vimpat, Neupro$109$22,18524 claims
SK Life Science, Inc.Xcopri$139$10,60741 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 702 neurology providers in Ohio.

Other neurology in Circleville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →